Content about hepatitis

December 13, 2013

According to published reports, Express Scripts may be looking to start a "price war" among the makers of the latest generation of drugs for hepatitis C — which promise much shorter treatment times than standard therapies, but also cost significantly more — in an effort to bring down prices.

The stakes are certainly high. According to Centers for Disease Control and Prevention, there are 3.2 million people in the United States chronically infected with hepatitis C and hence at risk for liver cancer, and the CDC recommends that anyone born between 1945 and 1965 get tested for the virus.

December 13, 2013

Pharmacy benefit manager Express Scripts hopes to drive down the cost of new drugs to treat hepatitis C by pitting their manufacturers against each other, according to published reports.

December 10, 2013

Nearly all patients taking an experimental treatment for hepatitis C developed by AbbVie were cured, the drug maker said Tuesday.

December 9, 2013

Giant Eagle on Monday announced the acquisition of Rx21 Specialty Pharmacy, enabling the company to provide enhanced services to Hepatitis C and organ transplant patients and providers.

December 6, 2013

The Food and Drug Administration has approved a new drug for hepatitis C made by Gilead Sciences, the drug maker said Friday.

November 25, 2013

The Food and Drug Administration has approved a new treatment made by Johnson & Johnson for hepatitis C, the drug maker said.

November 20, 2013

Following actions by the Food and Drug Administration, USPLabs has agreed to recall and destroy the dietary supplement OxyElite Pro, as it has been linked to dozens of cases of acute liver failure and hepatitis, including one death and illnesses so severe that several patients required liver transplants, the agency noted Wednesday.

October 24, 2013

An experimental drug under development by Gilead Sciences for hepatitis C is safe and effective when combined with other treatments, according to a review posted on the Food and Drug Administration's website ahead of an expert panel meeting to take place Friday.

October 10, 2013

A subsidiary of Johnson & Johnson has acquired rights to an experimental drug for hepatitis C from GlaxoSmithKline.

July 1, 2013

Walgreens on Monday received the third annual UnitedHealthcare “Shining Light: Leadership in Corporate Social Responsibility” award for excellence in social responsibility.

June 21, 2013

A bill passed by the New York state legislature will require baby boomers visiting healthcare providers to be offered a hepatitis C screening.

May 23, 2013

In anticipation of new treatments for hepatitis C, a growing number of physicians have begun intentionally delaying treatment for patients, according to a new study.

May 17, 2013

More than two-thirds of patients with hepatitis C achieved sustained virologic response or cure after completing newer “triple therapy” treatment, according to a Walgreens Specialty Pharmacy study released Friday.

March 4, 2013

Automatic spending cuts stemming from the failure of Congress and the White House to reach a budget deal will likely harm the disease-preventing capabilities of the Centers for Disease Control and Prevention, according to a new report.

January 17, 2013

Boehringer Ingelheim Pharmaceuticals has enrolled the first patients in its late-stage trial of a treatment for hepatitis C, the drug maker said Thursday.

November 28, 2012

By the time Hurricane Sandy had finished sweeping up the East Coast, it left billions of dollars in damage and took dozens of lives.

November 19, 2012

The Food and Drug Administration has approved a drug for a condition that can complicate treatment for hepatitis C.

November 9, 2012

Drug maker Boehringer Ingelheim has created a website designed for patients with hepatitis C and advocates, the company said Friday.

June 14, 2012

Kadmon Pharmaceuticals earlier this month announced that it has launched a new 600 mg/day dose pack of Ribasphere RibaPak (ribavirin, USP), Kadmon's proprietary ribavirin regimen available in a daily, two-pill compliance package for enhanced therapy adherence.

April 20, 2012

Merck is testing two means of treating patients with chronic hepatitis C for anemia, a common side effect of certain treatments for the viral infection, the drug maker said.

February 22, 2012

Novartis plans to pay up to $440 million for rights to a drug for treating hepatitis C made by Enanta Pharmaceuticals, Enanta said.

January 18, 2012

Drug maker Gilead Sciences has completed its $11.2 billion acquisition of Pharmasset, Gilead said.

January 16, 2012

The Food and Drug Administration's latest message to consumers and healthcare professionals seems like a no-brainer: "Insulin pens are not for sharing."

January 6, 2012

The Food and Drug Administration has granted fast-track designation to a drug currently under development by Achillion Pharmaceuticals for hepatitis C, the company said.

© 2014 Drug Store News. All Rights Reserved.